Current state of biomarkers in ovarian cancer prognosis (Q38628964)

4 September 2017

title

Current state of biomarkers in ovarian cancer prognosis (English)

1 reference

4 September 2017

0 references

1 reference

Jeremy A Squire

0 references

Katrina K Au

1 reference

4 September 2017

Juliana A Josahkian

series ordinal

1 reference

4 September 2017

Julie-Ann Francis

series ordinal

1 reference

4 September 2017

Madhuri Koti

series ordinal

1 reference

4 September 2017

language of work or name

English

0 references

publication date

9 November 2015

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

page(s)

3187-3195

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

4 September 2017

1 reference

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Targeted therapies and clinical trials in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Current approaches and challenges in managing and monitoring treatment response in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

PARP inhibitors in ovarian cancer: current status and future promise

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Circumventing cancer drug resistance in the era of personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Whole-genome characterization of chemoresistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Microenvironmental regulation of therapeutic response in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Immune-mediated mechanisms influencing the efficacy of anticancer therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Immunogenic cell death in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

MicroRNAs as prognostic markers in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

MicroRNAs in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Immune surveillance of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Checkpoint blocking antibodies in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Immunoengineering: how nanotechnology can enhance cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Cancer immunotherapy out of the gate: the 22nd annual Cancer Research Institute International Immunotherapy Symposium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Classifying Cancers Based on T-cell Infiltration and PD-L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Immune classification of colorectal cancer patients: impressive but how complete?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

CD20+ B cells: the other tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Circulating inflammation markers and risk of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

The emerging role of CXC chemokines in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Cancer drug resistance: an evolving paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

The cancer biomarker problem

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Molecular markers for cancer prognosis and treatment: have we struck gold?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Current status and implications of microRNAs in ovarian cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

On the reproducibility of TCGA ovarian cancer microRNA profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

In 2014, can we do better than CA125 in the early detection of ovarian cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Ovarian cancer biomarker discovery based on genomic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

The prognostic landscape of genes and infiltrating immune cells across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

The emerging role of extracellular vesicles as biomarkers for urogenital cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

Characterization and proteomic analysis of ovarian cancer-derived exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.251

21 January 2018

Identifiers

DOI

10.2217/FON.15.251

1 reference

release_wt2yr574evfongfulwg2lmf6ci

4 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wt2yr574evfongfulwg2lmf6ci

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference